Werewolf to Study WTX-124 With Merck's Keytruda in Solid Tumors

By Colin Kellaher

Werewolf Therapeutics Inc. on Wednesday said it formed a collaboration and supply agreement with Merck & Co. to study Werewolf's WTX-124 product candidate in combination with Merck's blockbuster cancer drug Keytruda.

Werewolf, a Cambridge, Mass., biopharmaceutical company, said it plans to conduct a Phase 1 clinical trial to evaluate the safety and preliminary efficacy of WTX-124 as a monotherapy and in combination with Keytruda in patients with solid tumors.

Werewolf said it plans to file for U.S. Food and Drug Administration approval of the trial in the first half of 2022.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

08-18-21 0837ET